GoodRx (GDRX) Free Cash Flow Analysis: $94M FCF, Not $164M

FCF Performance Summary

Market Cap: ~$1.15B  |  Enterprise Value: ~$1.35B  |  Price: $3.38 (as of September 11, 2026)

"All-in" free cash flow here means operating cash flow less capital expenditure, where capital expenditure includes both hard property and equipment purchases and capitalized internal-use software. That second piece is the whole story for a company like GoodRx: hard capex was $3.5 million in 2025, effectively rounding error against a $797 million revenue base, while capitalized software ran $70.5 million. A free-cash-flow figure that only deducts the $3.5 million is not measuring the same thing this business actually spends to stay in operation.

Cash Generation Quality

GAAP net income was $30.4 million in 2025 against $93.9 million of all-in free cash flow, a gap that runs the opposite direction from the usual story of depreciation inflating cash flow above earnings. Here the driver is stock-based compensation: it is a real GAAP expense that depresses reported net income, then gets added back in the cash flow statement. Adjusted net income of $126.1 million, which already excludes SBC, converts to free cash flow at 74%, down from 86% in 2024 and 98% in 2021.

Stock compensation consumed 82% of 2025's free cash flow. FCF after subtracting SBC was $17.2 million for the year, and only $14.5 million, negative $22.3 million, negative $28.7 million and negative $16.1 million in the four years before that. Four straight years of essentially zero cash accrual to owners once the dilution cost of paying employees in equity is counted as a cost, rather than added back as if it were free.

FCF/OCF conversion fell from 81% in 2021 to 56% in 2025 as capitalized software climbed. That decline is capex creep under a different name: the business isn't converting less of its operating cash into free cash because margins compressed, it's converting less because the reinvestment line that funds the platform has more than doubled.

FY2025 Capital Allocation Breakdown

Buybacks alone exceeded the year's entire free cash flow by 2.3x, funded by running down the balance sheet rather than by cash the business generated in 2025. Cash fell from $448.4 million to $261.8 million over the year, and the four-year buyback total of $581 million since 2022 has taken the company from a $98 million net cash position to $226 million of net debt. Leverage is still modest at 0.8x EBITDA, so this isn't a solvency problem, but it is a capital-allocation one: the repurchases were concentrated at $4.45 to $4.61 a share in 2025, well above the $3.38 price today, and the company stopped buying back stock in the second quarter of 2026 as the price fell.

5-Year FCF Trend Analysis (FY2021–FY2025)

Free cash flow has not recovered a 2021 peak that was itself inflated by pandemic-era prescription volume, and the subsequent decline traces almost entirely to rising reinvestment and working capital rather than a shrinking core business.

         FY2021      FY2022      FY2023      FY2024      FY2025
         $144M       $92M        $83M        $114M       $94M

  5Y CAGR: -10.1%  |  3Y CAGR: +0.7%  |  5-Yr Avg: $105.2M

Trend Narrative

The 2021 figure of $144 million reflected a business still riding elevated pandemic-era prescription transaction volume, with capitalized software a modest $29.9 million and stock compensation still working through a post-IPO grant cliff at $160.5 million. Free cash flow fell to $92 million in 2022 and $83 million in 2023 as capitalized software nearly doubled to $54.7 million and Prescription Transaction volume began softening.

2024 brought a partial rebound to $113.5 million as adjusted EBITDA expanded to 32.8% margin, but 2025 reversed a chunk of that gain. Rite Aid's bankruptcy and reduced volume through one pharmacy benefit manager partner cost between $35 million and $40 million of transaction revenue, Prescription Transaction fell 6%, and monthly active consumers dropped 14%. Capitalized software climbed to $70.5 million and receivables consumed an additional $88 million as the newer Pharma Direct segment scaled, since manufacturer-funded contracts pay slower than the legacy pharmacy-fee business they're replacing.

Revenue grew a cumulative 7% between 2021 and 2025 while adjusted EBITDA grew 18% and free cash flow fell 35%. The entire gap sits in reinvestment and working capital, not in the operating business, and 2026 is shaping up as a genuine inflection: Pharma Direct grew 76% year over year in the second quarter, and full-year guidance has been raised twice since February.

Operating Cash Flow Context

Depreciation and amortization is not broken out as a standalone line in the fetched XBRL dataset; GoodRx's cash flow statement folds acquisition-related intangible amortization together with other non-cash add-backs. The more meaningful reinvestment signal for this business is the capitalized-software trend covered above, since hard property and equipment purchases have stayed under 1% of revenue in every year of the analysis period.

Capital Expenditure Profile

CapEx/D&A is omitted here since D&A isn't separately disclosed; CapEx/Revenue tells the more relevant story on its own. It has climbed every single year, from 4.6% to 9.3% of revenue, entirely on the back of capitalized internal-use software rather than physical infrastructure. For a software-driven prescription platform, that line is the true reinvestment rate, and its steady climb is the mechanical reason free cash flow has not kept pace with EBITDA growth.

FCF Quality Score: 5/10 — Mixed, Improving

A 5/10 reflects a business with real and growing operating cash generation that converts into comparatively little free cash flow for owners once the true cost of the reinvestment and equity compensation is counted. Operating cash flow of $167.9 million in 2025 is solid for a $797 million-revenue company, but FCF/OCF conversion has fallen from 81% to 56% over five years, and FCF after stock compensation has been near zero for four consecutive years.

On the positive side, stock compensation has fallen sharply in absolute terms, from $160.5 million in 2021 to $76.6 million in 2025, and the business carries only 0.8x net debt/EBITDA even after $581 million of buybacks. Adjusted earnings convert to cash at a respectable 74% to 98% across the period, and the 2026 operating results, with Pharma Direct revenue up 76% to 82% across the first two quarters, suggest the multi-year revenue mix shift is landing faster than management projected in February.

Weighing against the score: days sales outstanding jumped from 67 to 108 in 2025 as the newer, cash-hungrier Pharma Direct segment scaled, an $88 million receivables build that was the largest single drag on the year's cash flow. Capitalized software has more than doubled since 2021 and shows no sign of plateauing. Management has not stated a free-cash-flow or conversion target on any of the last four earnings calls.

The structural risks that could impair free cash flow further: Pharma Direct is concentrated in GLP-1 manufacturer funding and now touches the federal TrumpRx program, both exposures with underdeveloped track records; the legacy Prescription Transaction segment is still declining toward a consensus $370 million in 2027, down 36% from 2024; and a receivables build that doesn't reverse would turn into either a permanent higher working-capital drag or a collections write-down.

Forward Outlook: Key Scenarios

The primary variable is whether the 2026 revenue mix shift toward Pharma Direct and subscriptions continues converting into cash as fast as it's converting into reported revenue, given the segment's slower collection cycle.

Scenario figures are illustrative sensitivities on steady-state free cash flow and an assumed exit yield, not forecasts or price targets.

Catalysts to Monitor

Days sales outstanding is the single most immediate signal: a move back toward 90 days while Pharma Direct still grows above 40% would indicate the segment is scaling without permanently degrading collections, while a further climb past 108 days would say the opposite.

Capitalized software as a share of revenue is the second variable worth tracking each quarter. It has risen every year since 2021; a management statement explicitly capping this line, or two consecutive quarters where it holds flat, would be a concrete signal that the reinvestment rate has found a ceiling rather than continuing to climb.

Stock compensation guidance matters directly to the owner-earnings math: SBC fell from $160.5 million to $76.6 million over five years, and continued progress toward the $60 million level referenced in the source data would push FCF after SBC meaningfully positive for the first time since 2021.

Revenue concentration is the fourth watch item. Pharma Direct was roughly 31% of second-quarter 2026 revenue, weighted toward GLP-1 manufacturers and now tied to the federal TrumpRx program; any indication that a major manufacturer partner is reducing funding or bringing cash-pay access in-house would remove the segment's primary growth engine.

Overall Assessment: GDRX FCF Quality Score 5/10

The central finding here isn't that GoodRx's cash flow is fake — the $167.9 million of 2025 operating cash flow is real and SEC-verified. It's that the free-cash-flow figure most screens and data providers report for this company overstates the cash actually available to owners by treating $70.5 million of capitalized software as if it weren't a capital expense, and treating $76.6 million of stock-based compensation as if it weren't a cost of running the business. Adjust for both and free cash flow after stock compensation summed to negative $19 million across 2022 through 2025.

The multi-year pattern shows where the risk actually sits: not in the reported top line, which grew every year except a managed 2025 decline, but in a receivables build that jumped days sales outstanding from 67 to 108 as the company shifted its revenue mix toward manufacturer-funded contracts that collect more slowly. A capital-allocation record that spent $581 million on buybacks at prices well above today's, funded partly from the balance sheet, compounds the picture rather than offsetting it.

A 5/10 quality score reflects a business in the middle of a genuine, verifiable operating improvement, without yet showing the free-cash-flow discipline, on capitalized software, stock compensation, and working capital alike, that would justify treating the headline 7.8% yield at face value. For more on how capitalized costs and equity compensation distort free cash flow comparisons, see Assessing FCF Quality and What Is a Good Free Cash Flow Yield?. For the underlying formula and how OCF and capex combine, see How to Calculate Free Cash Flow and Free Cash Flow vs. Net Income. The FCF Screener can be used to compare GDRX's yield and margin against other names using a consistent, capitalized-software-adjusted methodology.

⚠️ Disclaimer: This analysis is for educational and informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any recommendation to buy, sell, or hold any security. All financial data is sourced from publicly available SEC filings and is believed to be accurate as of the analysis date but has not been independently audited. Actual results may differ materially from any scenario estimates presented. FCF calculations use operating cash flow minus capital expenditures, inclusive of capitalized internal-use software; alternative definitions may yield different results. A direct, ticker-by-ticker peer FCF yield comparison is not included here because a dataset meeting the same sourcing standard as GoodRx's own SEC-filed figures was not available at analysis time; see the FCF Screener above for a broader cross-sector comparison. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal.

Data Sources

• GoodRx Holdings, Inc. Annual Reports (10-K): FY2021–FY2025 — SEC EDGAR XBRL (data.sec.gov)
• GoodRx Investor Relations Press Releases and Earnings Call Transcripts (Q3 2025 through Q2 2026)
• Market capitalization, enterprise value, and share price as of September 11, 2026